Understanding GLP-1 Therapies: What Patients Should Know

GLP-1 receptor agonists have become the most discussed class of medicine in a decade. Much of that discussion is about weight, which obscures what they were developed for and how they actually work.

What GLP-1 is

Glucagon-like peptide-1 is a hormone the gut releases after eating. It does several things at once: prompts the pancreas to release insulin when blood glucose is high, suppresses glucagon, slows how quickly the stomach empties, and signals fullness to the brain.

The natural hormone breaks down within minutes. GLP-1 receptor agonists are engineered to resist that breakdown, so a single injection can act for a day or a week.

Why the effect is glucose-dependent

The insulin release these drugs trigger only happens when blood glucose is elevated. That is why, used alone, they carry a low risk of hypoglycaemia — unlike insulin or sulfonylureas, which push glucose down regardless.

Combined with insulin or a sulfonylurea, the risk does rise, and doses of those are often reduced when a GLP-1 agonist is started.

The main agents

• Semaglutide — weekly injection; an oral daily form also exists
• Liraglutide — daily injection
• Dulaglutide — weekly injection
• Tirzepatide — weekly; acts on both GIP and GLP-1 receptors, and produces larger average effects on weight and HbA1c

Which is appropriate depends on the goal, other conditions, tolerance and availability.

What to expect, realistically

In type 2 diabetes, HbA1c reductions of roughly 1-2 percentage points are typical. Weight reduction varies widely by agent and individual — trial averages range from about 5% to over 20% of body weight.

Two points get lost in the coverage:

• Results are averages. Individual response varies substantially, and a minority respond minimally.
• The effect depends on continued treatment. Weight is commonly regained after stopping, which makes this a long-term therapy rather than a course.

Cardiovascular and kidney findings

Several agents in this class have demonstrated reductions in major cardiovascular events in dedicated outcome trials, and some have shown kidney benefit. This is why they are now positioned early in type 2 diabetes treatment for patients with established cardiovascular disease, rather than only after other options fail.

Side effects

The common ones are gastrointestinal — nausea, vomiting, diarrhoea, constipation — and are worst when starting or increasing the dose. This is why dosing escalates gradually over weeks rather than starting at target. For most people the effects settle.

Less common but important: pancreatitis, gallbladder disease, and — for some agents — a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Loss of muscle alongside fat is an active area of study, and adequate protein intake with resistance exercise is generally advised.

Questions worth asking

• Is the goal glucose control, weight, cardiovascular risk, or a combination?
• How does this interact with my other diabetes medicines?
• What is the plan if I cannot tolerate the escalation?
• What happens if I stop, and is this intended long-term?
• What supply continuity can I rely on?

That last question is not trivial. This class has seen repeated global shortages, and interrupted supply undoes progress.

Browse our diabetes range or the wider endocrine and metabolic catalogue.

This article is general information, not medical advice. Treatment decisions belong with a qualified clinician who knows your history. Every medicine mentioned is prescription-only and requires a valid prescription.